Payment overview · 2025
General Payments
$409.15
22 reported records · 13 companies
Healthcare provider profile · identity verified
Manik Mehra, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON, MO · NPI 1760745970
Verified facts
What the public records show
CMS Open Payments records show Manik Mehra, M.D. received $409.15 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 335 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.65 | 17.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.25 | 16.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.54 | 10.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.43 | 8.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.65 | 8.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.19 | 7.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.46 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.43 | 4.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.68 | 4.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.32 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.31 | 4.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.20 | 4.0% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $15.04 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $409.15 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $99.44 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
335 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
174 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 118 |
| Lisinopril | Lisinopril | 676 | 151 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 640 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 123 |
| Gabapentin | Gabapentin | 505 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 473 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 91 |
| Losartan Potassium | Losartan Potassium | 384 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 80 |
| Jardiance | Empagliflozin | 335 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 330 | 73 |
| Metformin Hcl Er | Metformin Hcl | 329 | 79 |
| Furosemide | Furosemide | 279 | 66 |
| Ozempic | Semaglutide | 270 | 42 |
| Potassium Chloride | Potassium Chloride | 269 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 256 | 41 |
| Omeprazole | Omeprazole | 247 | 57 |
| Tramadol Hcl | Tramadol Hcl | 237 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 70 |
| Metformin Hcl | Metformin Hcl | 212 | 42 |
| Glipizide Er | Glipizide | 209 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 179 | 25 |
| Eliquis | Apixaban | 174 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 46 |
| Buspirone Hcl | Buspirone Hcl | 150 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 131 | 102 |
| Donepezil Hcl | Donepezil Hcl | 130 | 20 |
| Sertraline Hcl | Sertraline Hcl | 129 | 24 |
| Finasteride | Finasteride | 126 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 52 |
| Alprazolam | Alprazolam | 123 | 38 |
| Clonazepam | Clonazepam | 121 | 27 |
| Fenofibrate | Fenofibrate | 119 | 17 |
| Carvedilol | Carvedilol | 117 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 16 |
| Trazodone Hcl | Trazodone Hcl | 114 | 24 |
| Mirtazapine | Mirtazapine | 113 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 25 |
| Famotidine | Famotidine | 104 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 13 |
| Tradjenta | Linagliptin | 97 | 19 |
| Myrbetriq | Mirabegron | 92 | 13 |
| Xarelto | Rivaroxaban | 89 | 12 |
| Allopurinol | Allopurinol | 88 | 15 |
| Spironolactone | Spironolactone | 88 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 13 |
| Pregabalin | Pregabalin | 84 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 21 |
| Ezetimibe | Ezetimibe | 80 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 80 | 19 |
| Montelukast Sodium | Montelukast Sodium | 76 | 16 |
| Olanzapine | Olanzapine | 76 | suppressed |
| Prednisone | Prednisone | 76 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 24 |
| Nystatin | Nystatin | 71 | 26 |
| Methocarbamol | Methocarbamol | 68 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 64 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Fluconazole | Fluconazole | 62 | 36 |
| Alendronate Sodium | Alendronate Sodium | 61 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 17 |
| Primidone | Primidone | 61 | suppressed |
| Mounjaro | Tirzepatide | 59 | 12 |
| Lorazepam | Lorazepam | 57 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Mupirocin | Mupirocin | 55 | 36 |
| Celecoxib | Celecoxib | 52 | suppressed |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Baclofen | Baclofen | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 11 |
| Sucralfate | Sucralfate | 44 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 43 | 43 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 20 |
| Torsemide | Torsemide | 42 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 42 | 13 |
| Ondansetron Odt | Ondansetron | 41 | 24 |
| Clindamycin Hcl | Clindamycin Hcl | 40 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Risperidone | Risperidone | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 11 |
| Hydrocortisone | Hydrocortisone | 36 | 18 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Cartia Xt | Diltiazem Hcl | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 19 |
| Azithromycin | Azithromycin | 21 | 11 |
| Cefdinir | Cefdinir | 21 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nystop | Nystatin | 20 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $409.15 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, FREESTYLE LIBRE, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, QULIPTA, REXULTI, SMARTVEST, TEZSPIRE, TONMYA, UBRELVY, WATCHMAN Access System, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error